A Single-Blind Trial of Risperidone vs. Paroxetine for Treatment of Panic Attacks

• Status: Completed
• Trial end date: 2003-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This study compares the efficacy of risperidone to that of paroxetine in the treatment of panic attacks in patients with Panic Disorder and with Major Depressive Disorder with Panic attacks and compares the side effect profile of risperidone vs. paroxetine in treatment of panic attacks and compares response rates of risperidone vs. paroxetine in treatment of panic attacks.

• Phase: N/A

Details

• Lead Sponsor: Beth Israel Medical Center
• Treatments: Paroxetine; Risperidone

Criteria

Inclusion Criteria:

• Males and females, ages 18-55.

• Ability to sign an informed consent

• Diagnosis of Panic Disorder, or MDD with Panic attacks, single episode, recurrent, or chronic

• HAM-A score >17

Exclusion Criteria:

• Alcohol or substance abuse within the last 6 months

• Current diagnosis of Obsessive-Compulsive Disorder

• Current diagnosis of Schizophrenia, Schizoaffective Disorder, or Bipolar Mood Disorder

• Use of antipsychotic medications over the two months preceding enrollment in the study

• Changes in antidepressant or mood stabilizer dosing over the two months preceding enrollment in the study

• Previous adverse reaction to risperidone or paroxetine.